Nature Medicine, Published online: 24 October 2026; doi:10.1038/s41591-026-04756-1
As presented at the ESMO Congress 2026: In a 5 year follow-up of survival and correlative data from the pivotal phase 3 RELATIVITY-047 trial comparing relatlimab plus nivolumab versus nivolumab alone in patients with metastatic or unresectable melanoma, statistically significant differences in progression-free survival, overall survival and melanoma-specific survival were seen with high baseline levels of LAG3 high CD8+ T cells associated with improved response in the combination arm.
